• SENSEX
    NIFTY 50
Market

Friday's top brokerage calls: SBI, Voltas and more

Updated : February 26, 2021 08:42 AM IST

Among brokerages, CLSA is bullish on SBI and raised its target price while Jefferies likes Voltas as AC sales likely to pick up in the onset of summer. Here are the top brokerage calls for today:

 CLSA on SBI : The brokerage has a 'buy' call on the stock and raised the target to Rs 600 per share from Rs 400 earlier. The brokerage also increased its profit estimates by 4-5 percent, adding that a stable margin will take the bank's RoA to 80-100 bps.
CLSA on SBI: The brokerage has a 'buy' call on the stock and raised the target to Rs 600 per share from Rs 400 earlier. The brokerage also increased its profit estimates by 4-5 percent, adding that a stable margin will take the bank's RoA to 80-100 bps.
 Jefferies on Voltas:  The brokerage has a 'buy' call on the stock with a target at Rs 1,250 per share. Dealer checks suggest a healthy trend in consumer durables demand, noted the brokerage. It sees AC sales picking up with the onset of summer.
Jefferies on Voltas: The brokerage has a 'buy' call on the stock with a target at Rs 1,250 per share. Dealer checks suggest a healthy trend in consumer durables demand, noted the brokerage. It sees AC sales picking up with the onset of summer.
 Morgan Stanley on oil and gas:  As per the brokerage, the pace of fuel price rise is surprising and should reduce investor concerns on margin. Marketing margins have turned positive with daily fuel revisions.
Morgan Stanley on oil and gas: As per the brokerage, the pace of fuel price rise is surprising and should reduce investor concerns on margin. Marketing margins have turned positive with daily fuel revisions.
 Nomura on Pharma:  The new PLI covers pharma formulations and API/intermediaries, said the brokerage, adding that the estimated annual incentive is in the range of Rs 3,800-Rs 4,300 crore in FY24-27. Aurobindo, DRL, Lupin, Cadila and Sun Pharma are likely to benefit, it added.
Nomura on Pharma: The new PLI covers pharma formulations and API/intermediaries, said the brokerage, adding that the estimated annual incentive is in the range of Rs 3,800-Rs 4,300 crore in FY24-27. Aurobindo, DRL, Lupin, Cadila and Sun Pharma are likely to benefit, it added.
Published : February 26, 2021 08:42 AM IST
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement